Comparison of two doses of leucovorin in severe low-dose methotrexate toxicity - a randomized controlled trial.

ABSTRACT:

Background

Leucovorin (folinic acid) is a commonly used antidote for severe toxicity with low-dose methotrexate, but its optimum dose is unclear, varying from 15 to 25 mg every 6-h.

Methods

Open-label RCT included patients with severe low-dose (≤ 50 mg/week) methotrexate toxicity defined as WBC ≤ 2 × 10^9/L or platelet ≤ 50 × 10^9/L and randomized them to receive either usual (15 mg) or high-dose (25 mg) intravenous leucovorin given every 6-h. Primary outcome was mortality at 30-days and secondary outcomes were hematological recovery and mucositis recovery.

Trial registration number

CTRI/2019/09/021152.

Results

Thirty-eight patients were included, most with underlying RA who had inadvertently overdosed MTX (taken daily instead of weekly). At randomization, the

SUBMITTER: Bhargava M 

PROVIDER: S-EPMC10197821 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature